UMR-996
 



Sans titre



UMR-996 INSERM - Paris-Sud University


Inflammation, Chemokines and Immunopathology



Inserm Center Clamart and faculty of Pharmacy Châtenay-Malabry



The UMR-996 is organized in 3 teams (team I, Immunoregulation, Chemokines and Viral Persistence; team II, Drug and Chemical Allergy, Immunotoxicology And Immunopathology; team III, Intestinal Microbiota and Macrophages In Liver Inflammation). It is composed of biologists combining expertise in the fields of Immunology, Virology, Pathophysiology and Toxicology and is connected to the commissions 5, 7 and 8 of Inserm. Some of us also have clinical activity thus promoting the development of translational research projects. Our objectives are to analyze the pathological mechanisms of three classes of diseases: immune (autoimmunity and immunodeficiencies) and inflammatory related to chemical agents / drugs or metabolic liver disorders. Our projects aim to understand the pathophysiological role of key cell effectors of the immune system (Dendritic cells, B cells, Neutrophils and regulatory T cells) and chemokines in immunological disorders, viral diseases and cancers associated with immune diseases (eg WHIM syndromes and myelodysplastic syndromes, Idiopathic CD4 T Lymphopenia) and the production of autoantibodies characteristic of autoimmune diseases (eg lupus erythematosus) (Team I). Projects involving the analysis of inflammatory diseases induced by adjuvants or chemical or drug agents have focused on the roles of the transcription factor Nrf2, the neutrophil, Dendritic cells and T-cell responses (Team II). Regarding the pathogenic mechanisms of liver inflammation due to excessive alcohol consumption and metabolic syndrome, our projects are more specifically targeting the role of gut microbiota and liver resident macrophages (eg Kupffer cells) (Team III).

Original therapeutic strategies are being developed by the three teams in the LabEx LERMIT "Laboratory of Excellence in Research on Medication and Innovative Therapeutics"(http://www.labex-lermit.fr/) with the aim of identifying antagonists of the chemokine CXCL12 and its receptors, immunomodulator liposomes in the context of hepatic inflammation, and therapeutic targets for the control of autoimmune B cells in the context of Lupus erythematosus, and of analyzing resistance mechanisms to immunotherapies in autoimmune and inflammatory syndromes (eg rheumatoid arthritis). The UMR-996 is also a partner of an EQUIPEX project dedicated to the innovative "mass cytometry" technology or CyTOFTM.


Two teams are also part of a DHU "Département Hospitalo-Universitaire": Team II is member of the DHU "TORINO: Thorax innovation" and team III of the DHU "Hepatinov". The unit belongs to the SFR-US IPSIT "Institut Paris-Sud d'Innovation Thérapeutique" (http://www.ipsit.ifr141.u-psud.fr/site/fr/) allowing the access to the 8 technical platforms of the US, 3 of which being localized in the Clamart Inserm center (PHIC, PLAIMMO, ANIMEX). The three teams are part of the Doctoral School "Innovation Thérapeutique: du Fondamental à l'Appliqué".





 




MonSite, création et hébergement gratuit de sites web